Could engineered immune cells free diabetics from insulin shots?
NCT ID NCT07528105
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a single infusion of genetically modified immune cells (CAR-T cells) designed to target and calm the immune attack that causes type 1 diabetes. Nine adults with early-stage type 1 diabetes will receive the cells and be monitored for safety, insulin needs, and beta-cell function. The goal is to see if this approach can preserve the body's ability to produce insulin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogeneic CD7-targeted CAR-T cells (RD13-02)
What this could lead to
If it works, this could point toward a way to preserve the body's own insulin production and reduce dependence on insulin injections for people with early type 1 diabetes.
What could go wrong
This is a very early, small trial (9 people) testing safety first. The treatment may not work, could cause serious side effects, and any benefit may be temporary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T1DM - TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, 201508, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••